An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

ÇİÇİN, İRFAN; Oukkal, Mohammed; Mahfouf, Hassen; Mezlini, Amel; Larbaoui, Blaha; Ben Ahmed, Slim; Errihani, Hassan; Alsaleh, Khalid; Belbaraka, Rhizlane; Yumuk, Perran; Goktas, Burçe; ÖZGÜROĞLU, MUSTAFA

doi:10.4274/ejbh.galenos.2021.2021-9-9

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

Atıf İçin Kopyala

ÇİÇİN İ., Oukkal M., Mahfouf H., Mezlini A., Larbaoui B., Ben Ahmed S., ...Daha Fazla

EUROPEAN JOURNAL OF BREAST HEALTH, cilt.18, sa.1, ss.63-73, 2022 (ESCI)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 18 Sayı: 1
Basım Tarihi: 2022
Doi Numarası: 10.4274/ejbh.galenos.2021.2021-9-9
Dergi Adı: EUROPEAN JOURNAL OF BREAST HEALTH
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.63-73
Anahtar Kelimeler: subcutaneous, trastuzumab, breast cancer, HER2, patient satisfaction, ADJUVANT CHEMOTHERAPY, FINAL ANALYSIS, SAFETY, TOLERABILITY, EXPERIENCE
İstanbul Üniversitesi Adresli: Evet

Özet

Objective: This study was designed to investigate treatment satisfaction in patients and Health Care Professionals (HCP) and to evaluate the safety and tolerability of subcutaneous (SC) trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC).